There are currently 2869 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
NCT05674396
Recruiting
To learn if it is effective to use advanced radiation treatment techniques (stereotactic radiation or "SBRT") to safely deliver a strong dose of radiation to your tumor in a shorter period of time than would typically be feasible with traditional methods.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue
NCT06127797
Recruiting
To create a registry (database) of participants who come in for breast MRI scans. Researchers want to use this information to study if participants with dense breast tissue (tissue that is more difficult to see on mammogram).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/07/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Register for Updates
Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients
NCT05550298
Recruiting
The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT). Primary Objective To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors. Secondary Objectives: * To develop and validate a classifier based on pre-transplant immunological profi... Read More
Gender:
ALL
Ages:
18 years and below
Trial Updated:
01/06/2025
Locations: Baylor College of Medicine, Houston, Texas +2 locations
Conditions: Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
Register for Updates
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT05907304
Recruiting
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
01/06/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced or Metastatic Solid Tumors
Register for Updates
Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae
NCT03506308
Recruiting
This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV Drug Coated Balloon (DCB) PTA Catheter in subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: HCA Houston Healthcare, Houston, Texas +2 locations
Conditions: Arteriovenous Fistula
Register for Updates
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
NCT06594991
Recruiting
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: MD Anderson Cancer Center (Data Collection Only), Houston, Texas
Conditions: Advanced Melanoma
Register for Updates
Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
NCT02916810
Recruiting
The purpose of the study is to test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry. The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas (such as the auditory and language processing cortex). The investigators predict that such modulation will correct abnormal activities in patients... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
01/06/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Schizophrenia and Related Disorders
Register for Updates
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
NCT04634916
Recruiting
A prospective, single-arm, multi-center post-market surveillance study of the BD® WavelinQ™ EndoAVF System for the Creation of Arteriovenous (AV) Fistula in Patients Requiring Dialysis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: Houston Methodist, Houston, Texas +1 locations
Conditions: Kidney Disease, End-Stage, End-stage Renal Disease, Arteriovenous Fistula
Register for Updates
Outcomes of Low-Risk Endometrial Cancer with Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective, Multicenter, Cohort Study
NCT06689956
Recruiting
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
Gender:
ALL
Ages:
All
Trial Updated:
01/06/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
Register for Updates
Treating Breast Cancer Patients Undergoing Trastuzumab Treatment with Carvedilol to Reduce Incidence of Heart Failure
NCT03879629
Recruiting
Breast cancer patients undergoing trastuzumab-based HER2-directed therapy are at risk of heart function decline or heart failure symptoms, but it is unknown if, when, and for how long cardiovascular protective strategies, e.g. with a beta-blocker, could help. This study randomly assigns those taking curative-intent trastuzumab-based HER2-directed therapy to the beta-blocker carvedilol-either when significant heart function decline or subtle early signs of heart injury (either by elevation of a c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced And/or Metastatic Breast Cancer
NCT06515470
Recruiting
The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where parti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2025
Locations: Biotheryx Investigative Site, Houston, Texas
Conditions: Breast Cancer
Register for Updates